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Prognostic significance of a single positive result
of the RT-PCR tyrosinase assay for cutaneous melanoma patients
without distant metastases
Piotr Rutkowski1, Janusz A. Siedlecki2, Zbigniew I. Nowecki1, Jadwiga Kulig2,
W∏odzimierz Ruka1, Anna Wilczyƒska2, Zbigniew ˚urawski1
P u r p o s e. The aim of the study was to evaluate the prognostic value of a single assay of tyrosinase mRNA presence in peri-
pheral blood with the use of the polymerase chain reaction (RT-PCR) in patients with cutaneous melanoma without distant
metastases. We also attempted to analyze the tyrosinase test results in relationship to classic prognostic factors in malignant me-
lanoma.
Pa t i e n t s  a n d  m e t h o d s. We performed prospective studies on 119 patients with malignant melanoma in clinical stages
I-III (according to AJCC-UICC 1992) treated in the Soft Tissue/Bone Sarcomas Department of The M. Sk∏odowska-Curie
Memorial Cancer Center-Institute of Oncology in Warsaw. We analyzed the presence of tyrosinase mRNA in peripheral
blood, collected during the first follow-up visit using the RT-PCR method. Blood samples of 47 healthy volunteers and 10 pa-
tients with malignancies other than melanoma were taken as negative controls.
R e s u l t s. Positive results of the tyrosinase RT-PCR assay were observed in 25/119 patients (21%). We failed to find any sta-
tistical relationship between the results of tyrosinase RT-PCR assay and: Breslow’s primary tumor thickness, Clark’s level of
invasion, clinical stages I/II or III, pathological subtype of the primary lesion, patients’ sex. Median overall survival (OS) was
36.5 months. We were not able to reveal any differences in OS between the TYR/+/ and TYR /-/ groups.
C o n c l u s i o n. The results of the present study indicate that a single tyrosinase RT-PCR assay is not useful as a prognostic test
in patients with cutaneous malignant melanoma without distant metastases.
WartoÊç prognostyczna pojedynczego oznaczenia tyrozynazy metodà RT-PCR
we krwi obwodowej u chorych na czerniaka skóry bez przerzutów odleg∏ych
C e l  p r a c y. Celem badania by∏a ocena wartoÊci prognostycznej pojedynczego oznaczenia obecnoÊci mRNA tyrozynazy we
krwi obwodowej metodà reakcji ∏aƒcuchowej polimerazy (RT-PCR) u chorych na czerniaka skóry bez przerzutów odleg∏ych
oraz porównanie wyników testów na tyrozynaz´ z klasycznymi czynnikami prognostycznymi w czerniaku.
M a t e r i a ∏  i m e t o d y. Analizie poddano 119 chorych w stopniach I-III zaawansowania choroby (wed∏ug AJCC-UICC
1992), leczonych w latach 1994-1999 w Klinice Nowotworów Tkanek Mi´kkich i KoÊci Centrum Onkologii-Instytutu w War-
szawie. Wszystkim chorym pobrano pojedynczà próbk´ krwi obwodowej przy pierwszej kontrolnej wizycie od wykonania
zabiegu chirurgicznego. Z pobranej próbki krwi izolowano ca∏kowite RNA, a nast´pnie wykonano pojedyncze oznaczenie me-
todà RT-PCR, pozwalajàce na wykrycie mRNA tyrozynazy. Grup´ kontrolnà stanowi∏o 47 zdrowych osobników oraz 10 pa-
cjentów chorych na inne ni˝ czerniak nowotwory z∏oÊliwe.
W y n i k i. Pozytywny wynik testu tyrozynazowego TYR/+/ uzyskano w 25/119 przypadków (21%). We wszystkich przypadkach
kontrolnych nie stwierdzono obecnoÊci mRNA tyrozynazy. Nie wykazano zale˝noÊci statystycznej pomi´dzy wynikiem testu ty-
rozynazowego a: gruboÊcià zmiany pierwotnej wed∏ug Breslowa, stopniem nacieku wed∏ug Clarka, stopniem zaawansowania
I, II i III, podtypem histopatologicznym zmiany pierwotnej oraz p∏cià chorych. Âredni czas prze˝ycia w badanej grupie wyniós∏
oko∏o 36,5 miesiàca. Nie stwierdzono ró˝nicy w d∏ugoÊci prze˝ycia pomi´dzy grupami TYR/+/ i TYR/-/.
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Introduction
Malignant melanoma is a neoplasm, which originates
from melanocytes derived from the neural crest. The dia-
gnosis of cutaneous malignant melanoma among the whi-
te race is being established with rapidly increasing fre-
quency in developed countries. In Poland, in the period
from 1983 to 1993, the number of new incidences has in-
creased by 100% [1, 2]. Although the present results of
treatment of melanoma are better than some decades
ago, in Poland still about 50% of patients die of metasta-
tic disease. The identification of new prognostic featu-
res of the tumor has fundamental value, because it helps
to choose and design optimal treatment and can be useful
in assessing the course of the disease. Classic clinical and
pathological variables defining prognosis (tumor thick-
ness, level of invasion, tumor ulceration, primary lesion si-
te, pathologic subtype, patient’s sex, involvement of regio-
nal lymph nodes) remain the most important factors for
predicting disease progression [3-5]. However there is
a group of patients, who defy conventional prognostic
factors and in these cases the disease, in spite of favorable
features, has an unpredictable, aggressive and fatal cour-
se [6]. These problems indicate the necessity of deve-
loping newer individual tumor prognostic markers. Many
efforts have been undertaken to apply very sensitive im-
munological and molecular methods [4, 5, 7-9]. One of
the most promising potential candidates for cell-type-
-specific marker in melanoma is tyrosinase expression.
Tyrosinase (E.C. 1.14.18.1) – a key enzyme in melanin
synthesis – is actively transcribed only in melanocytes,
melanoma cells and Schwann cells [10]. Therefore, it se-
ems a prefect marker of the presence of circulating mela-
noma cells in peripheral blood. The application of rever-
se transcriptase polymerase chain reaction (RT-PCR) as-
say allows detecting the tyrosinase messenger RNA in
peripheral blood with high sensitivity.
RT-PCR for tyrosinase mRNA has been reported
as a useful technique for the detection of circulating tu-
mor cells in patients with melanoma. However, the re-
sults of different investigations have revealed incohe-
rent results with respect to the clinical and prognostic
value of tyrosinase RT-PCR [7, 11-16]. Thus far, publi-
shed results contained data of patients in all stages of
the disease and the percentage of positive results for
mRNA tyrosinase (TYR /+/) varies remarkably [7, 13,
17, 18]. It seems that in stage IV patients, when the dise-
ase is disseminated, melanoma cells should be present  in
peripheral blood, in a relatively large number but their
detection has practically no significance, because of the
refractory of the disease to established therapeutic me-
thods.
The aim of this prospective study, conducted at The
M. Sk∏odowska-Curie Memorial Cancer Center-Institu-
te (MSCMCCI) in Warsaw, was to estimate the progno-
stic value of a single RT-PCR tyrosinase test in patients
with cutaneous melanoma without metastases to distant
organs [stage I-III]. Subsequently, we attempted to corre-
late these results with important classic prognostic fac-
tors.
Materials and methods
Pa t i e n t s
All melanoma patients enrolled into the study (119 patients – 58
males, 61 females; mean age: 49.7 ± 12.8 years) with histological-
ly confirmed cutaneous melanoma were treated in The Soft Tis-
sue/Bone Sarcoma Department in MSCMCCI in Warsaw from
April 1994 to April 1999. Patients had not undergone any preli-
minary selection and none presented any features of distant
metastases. Peripheral blood samples were taken at the first ro-
utine follow-up visit. Oral informed consent was obtained from
all patients. All patients were followed up in routine visits at
the outpatient clinic. Follow-up time was 14-75 months (me-
dian 22 months).
Blood samples were also taken from 47 healthy volunteers
and 10 patients with other malignancies as negative controls.
A group of 16 patients with disseminated melanoma (6 – stage
IVA with in transit lower extremity metastases; 10 – stage IVB
with visceral metastases) was included for tyrosinase RT-PCR as-
say as well.
Clinical staging according to UICC-AJCC 1992 classifica-
tion was determined by physical examination, pathological exa-
mination of the primary lesion and/or involved lymph nodes
and routine imaging examinations (chest X-ray, ultrasonography
of the abdominal cavity) at the time of blood collection. There
were 10 patients in stage I, 56 – in stage II, and 50 with regional
lymph node involvement (stage III). Mean primary tumor thick-
ness according to Breslow in the group of patients in stage I, II
was: 4.2 ± 2.9 mm (median 3.5 mm). 72 patients (60%) had no-
dular melanoma (NM), 36 (30%) – superficial spreading mela-
noma (SSM), 8 (7%) – acral lentiginous melanoma and 3 (3%)
– lentigo malignant melanoma (LMM).
The patients’ clinical status was not known to persons run-
ning the RT-PCR assay and RT-PCR results were not known to
the surgeons recording disease status.
S y n t h e t i c  o l i g o n u c l e o t i d e s
All primers were synthesized using Applied Biosystems appara-
tus type 391. The primer sequences used in this work are presen-
ted in Tab. I.
R N A  i s o l a t i o n
Blood samples (5 ml) from melanoma patients and healthy do-
nors were collected on EDTA. The samples were centrifuged
(1500 g, 10 min) as soon as possible, and the plasma discarded.
At this point, the pellet of blood cells can be frozen at -70°C. The
RNA was prepared from a fresh or frozen pellet as described
previously [16].
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W n i o s k i. Wyniki pracy wskazujà, ˝e pojedyncze oznaczenie obecnoÊci mRNA tyrozynazy we krwi obwodowej w grupie cho-
rych na czerniaka skóry bez przerzutów odleg∏ych nie ma wartoÊci prognostycznej.
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Re v e r s e  P C R  m e t h o d s
For reverse transcription, 2 µg of RNA were dissolved in
12 µl of water containing 1.2 µg oligo(dT)12-18. The solution
was heated at 65°C for 10 min, then cooled to room temperatu-
re and supplemented to a final volume of 20 µl with 5 x reaction
buffer, 0.01 M DTT, 10 mM mixture of dNTPs, HPRI and
SuperScript reverse transcriptase according to conditions re-
commended by the producer (Gibco-BRL). The reaction mixtu-
re was incubated at 37°C for 1 h. The cDNA product was fur-
ther purified by phenol/chloroform extraction and precipita-
tion with 2.5 volumes of ethanol. The precipitated pellet was
dissolved in 15 µl of DEPC-treated water. The reaction mixtu-
re for the first round of PCR contained, in a final volume of 25
µl: 1 x PCR buffer, 200 µM of each dNTP, 1.5 mM MgCl2, 50 ng
of primers [Table I], 5 µl of purified cDNA solution and 2.5 u. of
Taq polymerase. The samples were heated to 94°C for 2 min
prior to amplification. Amplification conditions were as fol-
lows: 94°C for 45 sec, 60°C for 45 sec, 72°C for 45 sec; 30 cycles.
Amplification was finished by 10-min incubation at 72°C. Ream-
plification with nested primers was carried out under the same
amplification conditions. The resulting reamplification pro-
ducts (10 µl) were analyzed on 2% agarose with pUC 19 dige-
sted with Dde I restriction endonuclease as a molecular we-
ight standard.
RNA integrity was checked electrophoretically. The qu-
ality of cDNA was controlled by PCR using primers for human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH 1 and
GAPDH 2) [Table I].
S t a t i s t i c a l  A n a l y s i s
All statistical analyses were performed using STATISTICA So-
ftware [StatSoft] with the χ2 test for comparison between two
groups and Kaplan-Meier method and log-rank test for overall
survival (OS) analysis.
Results
Overall, among 119 tested patients there were 25 cases
(21%) of positive results of the tyrosinase mRNA RT-
-PCR test (TYR /+/).
Tyrosinase mRNA RT-PCR assay results did not cor-
relate with Breslow’s thickness or Clark’s level of invasion
of the primary lesion [Tab. II]. Tyrosinase test results did
not show any differences between the group of patients
with local disease (stage I, II) -12/69 TYR /+/ (17%) and
the group of patients with lymph node metastases (stage
III) – 13/50 (26%) [Tab. II]. No association between pa-
thological tumor subtype or patients’ gender and a positi-
ve RT-PCR for tyrosinase mRNA was revealed.
Tyrosinase mRNA was not detected among any ne-
gative control subjects (peripheral blood samples of heal-
thy volunteers or patients with malignancies other than
melanoma). No tyrosinase mRNA was also detected
when mRNA was isolated from fibroblast strains and
from other cancer cell lines.
The presence of the mRNA tyrosinase marker
(TYR/+/) was found in 8/10 cases in patients in IVB sta-
ge (in all cases of IVA, blood samples were negative for
tyrosinase TYR/-/). The percentage of TYR /+/ in clinical
stage IV was higher than those in patients with locoregio-
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Tab. II. RT-PCR tyrosinase test results and selected clinicopathological parameters in melanoma patients
Clinicopathological feature Number (percentage) of TYR/+/ patients Statistical 
N (%) significance; p-value
Breslow’s thickness of primary lesion (clinical stage I, II)
<4,0 mm 5/38 (13%) p = 0.4790
>4,0 mm 7/31 (23%) N.S.
Clark’s level of invasion of primary lesion (clinical stage I, II)
Clark II, III 6/40 (15%) p = 0.7960
Clark IV ,V 6/29 (21%) N.S.
Clinical stage
Local disease (I, II) 12/69 (17%) p = 0.3290
Lymph node metastases (III) 13/50 (26%) N.S.
Clinical stage
Locoregional disease (I, II, III) 25/119 (21%) p = 0.0262
Distant metastases (IV) 8/16 (50%) (p<0.05)
Pathological subtype of primary melanoma
NM 8/40 (20%) p = 0.9368
SSM 4/23 (17%) N.S.
Gender
F 17/61 (28%) p = 0.3332
M 8/58 (14%) N.S.
N.S. – not significant statistically
Tab. I. Sequences for polymerase chain reaction primers
Name 5’-sequences-3’ Length
of primer of the band
GAPDH 1 GGTCGGAGTCAACGGATTTG 
GAPDH 2 ATGAGCCCCAGCCTTCTCCAT 320 bp
HTYR 1 TTGGCAGATTGTCTGTAGCC
HTYR 2 AGGCATTGTGCATGCTGCTT 284 bp
HTYR 3 GTCTTTATGCAATGGAACGC
HTYR 4 GCTATCCCAGTAAGTGGACT 207 bp
nally advanced melanoma – stage I-III (21% vs. 50%)
[p<0.05].
Kaplan-Meier survival curves are shown in Fig. 1.
At the time of this analysis, 46 patients from the studied
group had died of the disease (39%). Median OS was
36.5 months. There were no significant differences in OS
between TYR /+/ and TYR /-/ groups of patients.
Discussion
Generally, the presence of circulating tumor cells in
peripheral blood can indicate the potential development
of secondary disease, which may have a negative influ-
ence on patients’ survival and predict tumor disse-
mination. Since the number of circulating melanoma
cells in the peripheral blood cell population is very low,
the technique for their detection has to be not only high-
ly sensitive, but also tumor-specific. The sensitive mole-
cular method of choice for the detection of circulating tu-
mor cells applied in a number of tumor types is RT-PCR.
At first, results of papers analyzing the role of the tyro-
sinase RT-PCR assay in clinical assessment of pa-
tients with cutaneous melanoma seemed very promising
[18-20]. However, the small number of investigations
were performed on patients with disease limited only to
local or lymph nodal disease [7, 12,21], and overall survi-
val was rather rarely analyzed in these groups in correla-
tion to results of tyrosinase RT-PCR tests. Moreover, re-
sults of the tyrosinase RT-PCR assay published by diffe-
rent research groups showed some discrepancies [12, 13,
17, 22] and indicated that better sensitivity and reliabili-
ty of tests can be achieved by searching and adding addi-
tional molecular markers, specific to melanoma cells [7,
16, 18].
We have previously reported on the RT-PCR assay
for tyrosinase mRNA of melanoma cells in peripheral
blood [16, 19]. Using this method, it was possible to detect
a single melanoma cell in 5 ml of normal blood. We have
also shown that the tyrosinase RT-PCR assay is a highly
specific technique. We have not observed any positive re-
sults of the assay in total RNA isolated from healthy indi-
viduals, patients with other malignancies, nor in total
RNA isolated from fibroblast strains, breast, colorectal or
lung cancer cell lines [16, 19].
The main purpose of our study was to assess the
prognostic value of a single tyrosinase RT-PCR assay in
the group of cutaneous melanoma patients without meta-
stases to distant organs (I, II and III in UICC staging).
The assay was usually performed on RNA isolated from
a single sample of peripheral blood taken a short time
(not more than 1-3 months) after removal of the primary
lesion. We have found tyrosinase mRNA amplification
in only 21% of cases. This percentage value is slightly lo-
wer than that observed previously by others [15, 13, 24].
The small number of positives may be caused by false-ne-
gative results. These may reflect the discontinuous release
of metastatic cells into the blood stream or a very low le-
vel of expression or even the absence of tyrosinase mRNA
caused by undifferentiation of melanoma cells. On the
other hand, taking into account only less advanced ca-
ses, compared to those presented by Proebstle et al. [11]
and Mellado et al. [21], the number of TYR /+/ is very si-
milar. Positive results of the tyrosinase RT-PCR assay in
these papers were obtained in stages I, II in 11-19% of ca-
ses and 15-31% in stage III.
Data presented by other authors demonstrated con-
tradicting and questionable results regarding the correla-
tion of tyrosinase RT-PCR assay and survival [12-14, 18].
According to our results, there is no correlation between
the results of the tyrosinase RT-PCR assay and treatment
outcomes in patients with localized or nodal disease. We
did not observe any significant differences between the su-
rvival time in the group of TYR/+/ and TYR /-/ (median
OS time 36 and 38 months, respectively).
In some reports it has been suggested that the pre-
dictive value for the tyrosinase RT-PCR assay can be im-
proved by the use of PCR assays for several different me-
lanoma markers [7, 16, 18]. Palmieri et al. [18], in a paper
based on 235 melanoma cases demonstrated that a single-
-marker tyrosinase RT-PCR assay was not reliable for
predicting the course of disease. According to this re-
port, a multiple-marker RT-PCR assay using additionally
p97, Melan/MART 1 and MUC 18 (this last marker has
been recently found in the blood of healthy persons –
with over 20% of false-positive results [7, 16]) increased
the efficacy of this assay as a prognostic test.
The spreading of disease to the regional lymph nodes
significantly affects the prognosis and increases the risk of
distant metastases. Despite large variables in percentage
of positive tyrosinase RT-PCR, several authors have re-
ported a correlation between positive tyrosinase tests and
clinical stages [13, 15, 21, 24]. In the present study no
differences were found for positive tyrosinase RT-PCR
assay incidences in the group of patients with the lesion li-
mited to the primary site on the skin and group of pa-
tients with lymph node involvement. However, it is worth
mentioning that the percentage of TYR /+/ for patients
with lymph node metastatic disease was slightly higher
than that of patients with localized disease (26% vs. 17%;
N.S.). Nevertheless the number of TYR /+/ increased si-
gnificantly among patients with metastatic melanoma
(stage IV). These positive results concerned mainly pa-
tients with visceral metastases. It is remarkable that
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Fig. 1. Overall survival in TYR/-/ and TYR/+/ groups of patients
TYR/+/ was not detected in any case of in transit dissemi-
nation in the lower limb (that is in this very particular
manifestation of lymphatic dissemination). Using different
molecular markers in their tests, Curly et al. [7] demon-
strated results, which revealed melanoma circulating cells
in peripheral blood samples of all (6/6) patients with in
transit skin metastases.
Our data also confirmed the suggestions of other
authors that there is no correlation between positive re-
sults of the tyrosinase RT-PCR assay and the most im-
portant conventional prognostic factor, that is Bre-
slow’s thickness of the primary lesion for stage I, II. The-
se data indicate that tumor progression may depend not
just on primary pathological parameters.
In conclusion, our results reinforce the statement
that a single test for the presence of tyrosinase mRNA has
no prognostic value in the group of melanoma patients wi-
thout distant metastases The results of our study also
support the hypothesis about great heterogeneity of tyro-
sinase expression in melanoma cells. The solution of this
problem can be either the serial examination of tyrosina-
se mRNA in peripheral blood of patients during consecu-
tive follow-up visits over a long period of time after initial
treatment or using the above-mentioned additional mar-
kers to complement tyrosinase [7, 16, 21]. So far, the de-
tection of micrometastases in an anatomical compart-
ment different than blood, that is the sentinel lymph no-
de biopsy technique [2], has the most important clinical
relevance in establishing the group of patients with a high
risk of developing metastases.
Piotr Rutkowski M.D.
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